Pomerantz Law Firm is examining claims from investors of EyePoint, Inc. regarding potential securities fraud linked to recent trial results.

Eyepoint and Rentschler Biopharma are among 38 companies sharing nearly $40 million in Massachusetts life sciences tax incentives.

Pomerantz LLP investigates potential securities fraud by EyePoint, Inc., urging its investors to take legal action following a significant stock drop.

EyePoint Pharmaceuticals is attempting to salvage its lead drug candidate, DURAVYU, by characterizing a failed Phase III trial as a statistical anomaly. The company is now focusing on secondary endpoints and a second upcoming study. The LUGANO trial, which evaluated the drug for wet age-related macu

Pomerantz LLP is conducting an investigation on behalf of EyePoint, Inc. investors. Concerns arise over potential securities fraud linked to a recent clinical trial announcement.

Priced at $3.66 per share, the options run for 10 years and vest over four years; 25% vests after year one, with the rest monthly.

Pomerantz LLP is probing claims from investors of EyePoint, Inc. regarding potential securities fraud, linked to disappointing trial results.

Kessler Topaz Meltzer & Check, LLP is investigating possible securities violations by EyePoint, Inc. after the stock plummeted 66% due to unfavorable trial results.

Pomerantz Law Firm is investigating claims related to EyePoint, Inc.'s potential securities fraud that left investors concerned after recent company announcements.

Reported Wednesday, Sep 2 - 5:48am EDT (TheFly subscription required to read more.)

Kessler Topaz Meltzer & Check, LLP is investigating EyePoint, Inc. following disappointing Phase 3 trial results. Investors may have legal options.

Although the trial did not meet its primary endpoint, EyePoint reported a 42% reduction in overall treatment burden, with most patients requiring zero or one supplemental injection through Week 56.

Pomerantz Law Firm is probing potential securities fraud at EyePoint, Inc. following troubling clinical trial results. Investors are advised to join the investigation.

EyePoint Pharmaceuticals' shares plummeted by around 70% after failing to meet crucial trial endpoints. Investors are urged to seek restitution.

EyePoint Pharmaceuticals is under scrutiny after revealing significant stock value losses due to a failed trial. Investors may pursue legal claims.

Reported Wednesday, Aug 19 - 4:21am EDT (TheFly subscription required to read more.)

The phase 3 LUGANO trial investigating Duravyu for wet AMD did not meet its primary endpoint in the full dataset but showed positive results in treatment burden, supplement-free rates and anatomic control, according to a press release. The randomized, double-masked, noninferiority LUGANO and LUCIA programs are investigating the safety and efficacy of Duravyu (vorolanib intravitreal insert, EyePoint Pharmaceuticals) vs. on-label aflibercept 2 mg as a treatment for wet age-related macular degeneration, with more than 900 patients enrolled across both trials. The primary endpoint looked at

The phase 3 LUGANO trial investigating Duravyu for wet AMD did not meet its primary endpoint in the full dataset but showed positive results in treatment burden, supplement-free rates and anatomic control, according to a press release. The randomized, double-masked, noninferiority LUGANO and LUCIA programs are investigating the safety and efficacy of Duravyu (vorolanib intravitreal insert, EyePoint Pharmaceuticals) vs. on-label aflibercept 2 mg as a treatment for wet age-related macular degeneration, with more than 900 patients enrolled across both trials. The primary endpoint looked at

RBC Capital downgrades its rating on EyePoint Pharmaceuticals to Sector Perform from a previous Outperform rating. EyePoint is a pharmaceutical company that develops treatments for serious eye…

Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal

Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal

Reported Tuesday, Aug 18 - 8:01am EDT (TheFly subscription required to read more.)

25 articles from 8 sources covering $435M+ in M&A deals, FDA regulatory moves including a generative AI device framework, clinical setbacks at Regeneron and EyePoint, and a bullish CDMO outlook driven by recovering biotech funds.